Project Grant R43AI174349
Award Date 3/7/23
Completion Date 2/28/25
Dollars Obligated $1.2M
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Pennsylvania, USA
Similar Awards
- The U.S. Defense Health Agency awarded a $4,728,039 Project Grant to HBVtech, L.L.C., a minority-owned small disadvantaged business located in Germantown, Maryland, under the Military Medical Research and Development program (CFDA 12.420). The grant supports the development of a new hepatitis B virus (HBV) cure treatment regimen aimed at the durable elimination of HBV covalently closed circular DNA (cccDNA) in chronic HBV infections. The research activities focus on exploring unconventional...
- This $847,428 federal Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 Allergy and Infectious Diseases Research) supports research to understand the mechanisms of hepatitis B virus (HBV) persistence and clearance in chronic hepatitis B patients, with a focus on evaluating intrahepatic cccDNA and integrated DNA. The primary awardee, Beth Israel Deaconess Medical Center, will conduct translational research to quantify cccDNA and integrated DNA levels,...
- The National Cancer Institute (NCI) awarded Imcare Biotech, Inc. a $364,763 Project Grant under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop and validate SERAVUE AI, a novel multi-analyte algorithmic assay for early detection of hepatocellular carcinoma (HCC), the most common type of primary liver cancer. The project aims to create a highly accurate, non-invasive blood test for HCC surveillance that could potentially replace ultrasound as the standard screening...
- This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $320,863 to Jericho Sciences, LLC to support the translational development of a small molecule therapeutic for the treatment of chronic hepatitis B virus (HBV) infection. The project aims to validate the proposed drug target, the hepatitis B X regulatory protein (HBx), which plays a critical role in HBV covalently...
- This $575,356 Project Grant was awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research federal grant program (CFDA 93.855) to The Trustees of Columbia University's Health Sciences Division on August 8, 2025. The funding supports the development of a rapid, multiplexed RT-PCR diagnostic for detecting hepatitis C virus (HCV) infection directly from whole blood samples. The proposed approach leverages plasmonic-based...
- The National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855), awarded a $884,453 Project Grant to Brigham & Women's Hospital Inc. to develop a rapid, cost-effective point-of-care (POC) diagnostic test for Hepatitis C Virus (HCV) detection. The 5-year project, which commenced on November 22, 2024, aims to create a highly sensitive and specific HCV antigen (Ag) testing solution that can streamline...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $258,750 Project Grant under the Allergy and Infectious Diseases Research federal grant program (CFDA 93.855) to HBVTech, LLC, a small disadvantaged business located in Germantown, Maryland. The grant funding supports the development of HBVZ10, a new gene therapy candidate aimed at producing sustained high levels of anti-hepatitis B surface antigen antibodies to block hepatitis B virus (HBV) reinfection and potentially...
- This $510,306 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to advance the understanding of virus-host interactions for developing a cure against chronic hepatitis B virus (HBV) infections. The primary goal is to investigate the mechanisms by which interferon-alpha treatment can lead to a functional cure for HBV, as well as explore the impact of HBV...
- The U.S. Centers for Disease Control and Prevention (CDC) awarded a $233,666 Project Grant to Esper Biosciences Inc. in Ithaca, NY on September 30, 2025 under the CDC Investigations and Technical Assistance program (CFDA 93.283). The grant funding supports the development of a rapid point-of-care nucleic acid test for Hepatitis C using nanosensors. This project aligns with the CDC program's goals of controlling communicable diseases and developing innovative health technologies. The award has...
- This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Phase I Small Business Technology Transfer (STTR) project aims to develop a novel, cost-effective, and rapid CRISPR-Cas12a diagnostic platform to screen newborns for congenital cytomegalovirus (CCMV). CCMV affects approximately 25,000 U.S. babies annually, leading to hearing loss and neurological issues in 25% of infected children with a 0.5% mortality rate. The $305,000 award to Cleaved Diagnostic...